CVS Health (CVS) just locked in extended pharmaceutical distribution agreements with Cardinal Health and McKesson through mid 2032, a long-dated supply commitment that gives investors clearer visibility on how medicines reach its pharmacies.
Recent trading has been choppy for CVS Health, with the share price down 10.66% over the past 30 days and 17.27% over 90 days, yet still up 7.86% year to date. That short term weakness contrasts with a 15.63% 1 year and 35.11% 3 year total shareholder return, suggesting longer term holders have seen steadier gains. At the same time, the fresh distribution extensions, dividend affirmation, and ongoing political scrutiny of pharmacy benefit managers are all feeding into how the market now prices CVS’s risk and resilience at around $86.43 per share.
Scan how the CVS Health story compares with other healthcare groups securing long-term supply and income resilience by reviewing the hand picked 31 resilient stocks with low risk scores now shaping the sector’s lower risk corner.
The pullback in CVS Health could be read as a verdict on its pharmacy benefit manager exposure rather than its fresh distribution security. The valuation work now is figuring out which story the current price reflects more.
Most Popular Narrative: 30% Undervalued
Against the last close at $86.43, the most followed narrative on CVS Health pegs fair value at $124, which frames today’s pullback as a valuation gap rather than a broken business model.
CVS Health is no longer the broken-Aetna-plus-drugstore story the market used for most of 2024 and 2025. Through the first half of 2026 the company has raised full-year guidance twice, Aetna’s medical benefit ratio has improved, cash flow is running well ahead of plan, and all three operating segments are growing. The stock still trades as if the insurance rebuild is temporary and the PBM is about to be regulated into irrelevance.
See why 2 investors see CVS Health as 30% undervalued.
According to andrei9868, this thesis leans on a few concrete markers. Guidance for 2026 revenue sits at a minimum of $414b, adjusted operating income is guided to between $16.58b and $16.92b, and cash from operations is expected to be at least $11.5b. Management has also outlined an adjusted EPS range of $7.90 to $8.10 for 2026, along with a stated 2027 adjusted EPS floor of at least $8.44.
The narrative points to this earnings and cash profile as the backbone for a $124 fair value estimate, which implies a material discount to that figure at the current share price. It also highlights that CVS Health carries a value score of 5 out of 6 on Simply Wall St’s checks and is trading 68.1% below the platform’s DCF based estimate of future cash flow value at $272.39 per share. On top of that, analysts as a group see scope for the price to rise by 33.9% from here, which lines up with the idea that today’s valuation still reflects old worries about the insurance and PBM businesses more than the updated guidance.
Result: Fair Value of $124 (UNDERVALUED)
Still, the thesis can crack if medical costs run hotter than expected, or if PBM reforms squeeze CVS Health’s Health Services profitability faster than anticipated.
Find out about the key risks to this CVS Health narrative.
Next Steps
If this CVS Health story sounds split between opportunity and risk, now is the moment to pull up the data and test it yourself, starting with the 4 key rewards and 2 important warning signs.
Hunting for more ideas beyond CVS Health?
Do not stop with a single story. Broaden your watchlist with a few focused screens that surface different types of opportunities other investors might overlook.
- Target resilient balance sheets and steadier fundamentals by scanning a list of solid balance sheet and fundamentals (25 results) that filters out weaker financial profiles.
- Chase value opportunities by reviewing a curated 27 high quality undervalued stocks that emphasizes quality alongside pricing that some investors may be misreading.
- Spot earlier stage potential by checking a tightly filtered 9 elite penny stocks with strong financials that focuses on stronger finances rather than pure speculation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com